Oncotelic Announces the launch of PDAO token
January 17, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...
Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives
January 04, 2023 16:15 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
December 28, 2022 07:00 ET
|
BIOXYTRAN, INC.
Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28,...
AnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022
December 19, 2022 16:15 ET
|
ANPAC BIO-MEDICAL SCIENCE CO., LTD.
PHILADELPHIA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
December 14, 2022 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...
Bioxytran Interview at the Emerging Growth Conference
December 12, 2022 09:45 ET
|
BIOXYTRAN, INC.
Wednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
December 08, 2022 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and...
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
November 22, 2022 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive...
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
November 15, 2022 08:00 ET
|
Vyant Bio, Inc.
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered...
Vyant Bio to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16
November 10, 2022 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...